Allos Pharma Inc. Receives FDA Guidance for the Design of a Phase 3 Trial to Support a New Drug Application for Treatment of Fragile X Syndrome

CAMBRIDGE, Mass., May 23, 2023. Allos Pharma Inc. ( " Allos " ), a biopharmaceutical company specializing in the development of treatments for rare neurological disorders, announced today that it has held a meeting with the U.S. Food and Drug...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials